Shingles Vaccine Market Size & Growth Forecast 2027–2036, By Segments (Vaccine Type, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Shingles Vaccine Market size was worth USD 6.3 billion in 2026 and is expected to grow at a 14.92% CAGR between 2027 and 2036, reaching USD 25.31 billion by 2036. The industry revenue for 2027 is assessed at USD 7.09 billion.
Get more details on this report
Request Free Sample ReportShingles Vaccine Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 60.39% share due to strong vaccine access, established adult immunization programs, reimbursement support, and pharmacy-based distribution channels enabling broad uptake.
- Asia Pacific is expanding at 17.02% CAGR driven by improving adult vaccination awareness, expanding healthcare access, and strengthening immunization infrastructure across large aging populations.
Segment Momentum
- Shingrix accounted for 89.43% of the market in 2026 due to its strong presence in vaccination programs, established prescribing practices, and well-developed commercial distribution and procurement channels.
- Live Attenuated Vaccine is the fastest-growing vaccine type as expanding regional immunization programs and favorable local procurement patterns create new opportunities for broader market adoption.
Market Expansion Drivers
- Expanding elderly population increasing demand for preventive shingles immunization programs globally.
- Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption.
- Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets.
Leading Market Participants
- Major companies in the shingles vaccine market include GlaxoSmithKline plc (United Kingdom), Merck & Co. Inc. (United States), Pfizer Inc. (United States), SK bioscience Co. Ltd. (South Korea), Green Cross Corporation (South Korea), Geneone Life Science Inc. (South Korea), CanSino Biologics Inc. (China), Moderna Inc. (United States), Vaccitech plc (United Kingdom), BioNTech SE (Germany).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.3 billion
- 2027 Estimated Market Size: USD 7.09 billion.
- Projected Market Size: USD 25.31 billion by 2036
- Growth Forecast: 14.92% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Recombinant Vaccine (Vaccine Type) | Shingrix (Product)
- Emerging Opportunity Segment: Live Attenuated Vaccine (Vaccine Type) | SKYZoster (Product)
Market Growth Drivers and Industry Trends
Expanding elderly population increasing demand for preventive shingles immunization programs globally
Population aging is creating a larger group of individuals vulnerable to shingles and its associated complications, supporting the shingles vaccine market as healthcare systems place greater emphasis on preventive protection among older adults. The risk of developing shingles increases with age because immune function can decline over time, making vaccination an important component of preventive healthcare for eligible populations. Greater awareness of age-related health risks is encouraging older adults, caregivers, and healthcare professionals to consider vaccination as part of routine disease prevention. Healthcare providers can also incorporate shingles immunization into broader adult vaccination programs, particularly when engaging with older patients during regular medical consultations.
Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption
Technological progress in recombinant vaccine development is strengthening confidence in preventive shingles vaccination and supporting the shingles vaccine market through improved vaccine performance and clinical utility. Recombinant approaches can enable the development of vaccines designed to generate a strong immune response without relying on live virus, offering an important technological pathway for adult immunization. Continued advances in vaccine formulation and immune-response optimization are helping address the needs of populations in which protection against shingles is particularly important. Greater clinical acceptance of effective recombinant approaches can also encourage healthcare professionals to incorporate vaccination more consistently into preventive care discussions for eligible adults.
Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets
Public health authorities are increasingly incorporating adult immunization into broader disease-prevention strategies, creating opportunities for the shingles vaccine market as vaccination coverage expands beyond traditionally emphasized childhood programs. Government-supported initiatives can improve awareness among older populations, facilitate access through organized healthcare channels, and encourage healthcare providers to recommend eligible adults for vaccination. In emerging healthcare systems, the development of stronger preventive-care infrastructure and adult vaccination programs can also help reduce gaps in access to recommended immunizations. Public-sector engagement is particularly important for reaching older populations who may have limited awareness of shingles prevention or may not routinely seek vaccination outside standard healthcare visits.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding elderly population increasing demand for preventive shingles immunization programs globally | 2.60% | High | North America, Europe | High | Near Term |
| Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption | 2.30% | High | North America, Asia Pacific | High | Mid Term |
| Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets | 2.00% | High | Asia Pacific, Latin America | Emerging | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The shingles vaccine market was led by North America, which accounted for a 60.39% share in 2026, reflecting strong vaccination infrastructure, high awareness of shingles prevention, and established adult immunization programs. The region benefits from extensive healthcare access and increasing emphasis on preventive care among aging populations, where the risk of shingles is more pronounced. Public health initiatives, physician recommendations, and greater awareness of complications associated with shingles are supporting vaccination uptake. Continued focus on reducing the healthcare burden associated with preventable diseases is also reinforcing demand for shingles immunization across the region.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, supported by aging populations, improving healthcare infrastructure, and increasing awareness of preventive vaccination. Governments and healthcare providers are placing greater emphasis on adult immunization and disease prevention as healthcare systems expand their focus beyond acute treatment. Rising awareness of shingles-related complications is encouraging more adults and healthcare professionals to consider vaccination, while improving access to vaccines through hospitals, clinics, and immunization programs is broadening the addressable population.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Preventive Healthcare AlignmentGermany supports shingles vaccination through established preventive healthcare practices and recommendations for older adults. Healthcare providers continue promoting vaccination awareness while integrating immunization into routine preventive care and primary healthcare services.
France 🇫🇷
Healthcare Access ReinforcementFrance strengthens shingles vaccination through coordinated healthcare services and preventive care strategies for eligible adults. The market supports greater physician engagement and improved patient awareness to encourage broader vaccination participation.
Italy 🇮🇹
Community Immunization FocusItaly promotes shingles vaccination through regional healthcare programs and preventive immunization initiatives aimed at older adults. Healthcare organizations continue emphasizing patient education and accessible vaccination pathways to support consistent immunization practices.
Japan 🇯🇵
Aging Population ProtectionJapan prioritizes shingles vaccination as part of broader efforts to reduce disease burden among its aging population. Public health initiatives and healthcare providers continue encouraging vaccination uptake through improved awareness and preventive healthcare engagement.
South Korea 🇰🇷
Preventive Vaccination UptakeSouth Korea continues expanding shingles vaccination through preventive healthcare initiatives targeting adults at elevated risk. Healthcare providers focus on increasing awareness, improving patient education, and incorporating vaccination into broader adult immunization practices.
United States 🇺🇸
Adult Immunization ExpansionThe U.S. shingles vaccine market emphasizes expanding adult immunization through preventive healthcare initiatives and broad healthcare provider engagement. Vaccination programs increasingly focus on improving awareness among eligible adults while strengthening access through pharmacies and healthcare networks.
Segment Leadership and Growth Trends
Shingles Vaccine Market Share (%), by Vaccine Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportVaccine Type Segment Analysis: Recombinant Vaccine (Largest Segment) vs Live Attenuated Vaccine (Fastest-Growing Segment)
The recombinant vaccine segment dominated the shingles vaccine market with an 89.43% share in 2026, supported by its strong relevance in shingles prevention programs and the growing focus on effective protection against the disease. Increasing awareness of preventive healthcare and the expanding emphasis on vaccination among populations at elevated risk are contributing to demand. Healthcare systems are also placing greater importance on reducing the clinical and economic burden associated with shingles-related complications.
The live attenuated vaccine segment is expected to be the fastest-growing segment, supported by continued demand for alternative vaccination approaches across different healthcare settings. Expansion of immunization initiatives and improving awareness regarding shingles prevention are contributing to broader vaccine adoption. Increasing efforts to improve access to preventive care are also expected to support segment growth.
Product Segment Analysis: Shingrix (Largest Segment) vs SKYZoster (Fastest-Growing Segment)
The shingrix segment held the largest share of the shingles vaccine market, accounting for 89.43% in 2026, reflecting its prominent position within shingles prevention and the strong focus on recombinant vaccination approaches. Rising awareness of shingles-related health risks and increasing emphasis on adult immunization are supporting demand for established preventive products. Expanding vaccination initiatives and greater engagement with preventive healthcare continue to reinforce the segment's leading position.
The SKYZoster segment is anticipated to be the fastest-growing segment as demand expands for additional shingles vaccination options across healthcare markets. Growing attention to preventive medicine, broader immunization access, and increasing awareness among eligible populations are expected to support adoption. Continued development of vaccination programs may further create growth opportunities for alternative product offerings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Vaccine Type | Recombinant Vaccine, Live Attenuated Vaccine | Recombinant Vaccine | Live Attenuated Vaccine |
| Product | Shingrix, Zostavax, SKYZoster | Shingrix | SKYZoster |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the shingles vaccine market:
1. GlaxoSmithKline plc (United Kingdom)
2. Merck & Co. Inc. (United States)
3. Pfizer Inc. (United States)
4. SK bioscience Co. Ltd. (South Korea)
5. Green Cross Corporation (South Korea)
6. Geneone Life Science Inc. (South Korea)
7. CanSino Biologics Inc. (China)
8. Moderna Inc. (United States)
9. Vaccitech plc (United Kingdom)
10. BioNTech SE (Germany)
The shingles vaccine market is expanding due to increasing focus on preventive healthcare and aging population needs. The shingles vaccine market is witnessing innovation in next-generation immunization technologies. Continuous research collaboration is improving vaccine efficacy and protection duration.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline plc (United Kingdom) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Pfizer Inc. (United States) | |||||||
| SK bioscience Co. Ltd. (South Korea) | |||||||
| Green Cross Corporation (South Korea) | |||||||
| Geneone Life Science Inc. (South Korea) | |||||||
| CanSino Biologics Inc. (China) | |||||||
| Moderna Inc. (United States) | |||||||
| Vaccitech plc (United Kingdom) | |||||||
| BioNTech SE (Germany). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Eli Lilly | Feb-26 | Eli Lilly executed definitive agreements to acquire Curevo, LimmaTech, and Vaccine Company in an aggregate transaction valued up to $3.8 billion. The multi-asset acquisition significantly expands Eli Lilly's pipeline across viral and bacterial pathogens, explicitly integrating Curevo's specialized assets to accelerate corporate entry and research capabilities within the next-generation shingles prevention market. |
| Sanofi | Feb-26 | Sanofi reached an agreement to acquire Dynavax Technologies for approximately $2.2 billion, absorbing its commercial immunization portfolio alongside Z-1018, an investigational Phase 1/2 shingles vaccine candidate. The strategic transaction accelerates Sanofi's competitive positioning in adult vaccinology, providing a direct pipeline entry point to challenge established market leaders in herpes zoster prevention. |
| Curevo Vaccine | Feb-26 | Curevo Vaccine secured $110 million in Series B venture financing led by Medicxi, with co-investment from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures. The capital infusion is strategically earmarked to fund the advanced clinical expansion and regulatory development of amezosvatein, the company's leading investigational shingles vaccine candidate. |
| EuBiologics | Feb-26 | EuBiologics disclosed positive interim data from its Phase 1 clinical trial of the EuHZV shingles vaccine candidate, demonstrating safety and immunogenicity profiles comparable to an active control vaccine. The clinical results establish a viable baseline to advance the candidate into larger efficacy trials, positioning the firm to contest the global shingles market. |
| GlaxoSmithKline (GSK) | Feb-26 | GlaxoSmithKline expanded the commercial footprint of its recombinant zoster vaccine, Shingrix, by launching the product in Malaysia. The geographic expansion broadens preventative healthcare access for adults aged 50 and older or those at elevated risk, reinforcing the company's dominant global market share in shingles prevention. |
| SK bioscience | Feb-26 | SK bioscience reorganized its operational focus to scale its commercial shingles vaccine portfolio, aiming to capture global market share unaddressed due to recent competitor product withdrawals. The defensive repositioning optimizes supply chain and manufacturing capabilities to align with rising seasonal demands for adult immunizations. |
| AIM Vaccine Co., Ltd. | Mar-25 | AIM Vaccine Co., Ltd. secured investigational clinical trial approval from the U.S. Food and Drug Administration for its independently developed mRNA shingles vaccine candidate. The regulatory clearance allows the company to initiate human trials within the United States, marking a critical operational milestone for mRNA platform validation in the competitive shingles prevention landscape. |
| GlaxoSmithKline (GSK) | Mar-25 | GlaxoSmithKline formed a specialized research coalition with the UK Dementia Research Institute and Health Data Research UK to execute a population-level health data study. The scientific initiative investigates a potential statistical correlation between Shingrix vaccination and reduced dementia incidence, potentially generating unique clinical differentiation and a new marketing paradigm for the asset. |
| Dynavax Technologies Corporation | Jun-24 | Dynavax Technologies Corporation initiated patient dosing in its Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of its investigational shingles vaccine candidate, Z-1018. This clinical milestone marks the early-stage commercial development of an alternative adjuvant-based therapeutic regimen designed to prevent herpes zoster reactivations. |
| SK bioscience | Jan-23 | SK bioscience obtained Biologics License Application approval from Malaysia’s National Pharmaceutical Regulatory Agency for its shingles vaccine, SKYZoster. This regulatory clearance marks the product’s second international market entry following its initial approval in Thailand, expanding the manufacturer's geographic footprint and commercial distribution network across Southeast Asia. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Shingles Vaccine Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Age Group | 50–59 Years, 60–69 Years, 70–79 Years, 80 Years and Above |
| Vaccination Setting | Hospitals, Physician Clinics, Retail Pharmacies, Community Vaccination Centers |
| Funding Source | Public Immunization Programs, Private Insurance, Employer-Sponsored Programs, Out-of-Pocket Payments |
Shingles Vaccine Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Aging Population Immunization Strategy |
|
| Adult Immunization Opportunity Assessment |
|
| Market Access and Reimbursement Analysis |
|
Need a different cut of the data?
Request Custom ResearchHow large is the shingles vaccine market?
What is the expected industry size of shingles vaccine by 2036?
How is population aging shaping procurement strategies in the shingles vaccine market?
Why are recombinant vaccine advancements accelerating adoption in the shingles vaccine market?
Why does Shingrix dominate the shingles vaccine market?
Which vaccine type is growing fastest in the shingles vaccine market?
Why does North America dominate the shingles vaccine market?
What is driving Asia Pacific’s growth in shingles vaccine adoption?
Who holds a significant market share in the shingles vaccine landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization